Low-dose human chorionic gonadotropin during the proliferative phase may adversely affect endometrial receptivity in oocyte recipients

Gynecological Endocrinology

Volumn 25, Issue 1, 2009, Pages 53-59

  Prapas, Nikos ^a,b   Tavaniotou, Asimina ^a   Panagiotidis, Yannis ^a   Prapa, Stella ^a   Kasapi, Evangelia ^a   Goudakou, Maria ^a   Papatheodorou, Achilleas ^a   Prapas, Yannis ^a  

^a Iakentro Fertility Center   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

Author keywords

Endometrium; Implantation rate; In vitro fertilization; Oocyte donation; Pregnancy rate

Indexed keywords

ARVECAP; CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GROWTH HORMONE RELEASING FACTOR; HUMAN MENOPAUSAL GONADOTROPIN; PROGESTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG EFFECT; ENDOMETRIUM; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NIDATION; OOCYTE; OOCYTE DONATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIDE EFFECT; UTERUS FUNCTION;

ADULT; CHORIONIC GONADOTROPIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO IMPLANTATION; ENDOMETRIUM; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMANS; INFERTILITY, FEMALE; MENOTROPINS; OOCYTES; PREGNANCY; PREGNANCY RATE;

EID: 60749090934     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802360769     Document Type: Article

References (48)

1. Huhtaniemi IT, Catt KJ. Differential binding affinities of rat testis luteinizing hormone (LH) receptors for human chorionic gonadotropin, human LH, and ovine LH. Endocrinology 1981;108:1931-1938.
2. Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989;52:398-400.
3. Filicori M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril 1999;71:405-414.
4. Shoham Z, Borenstein R, Lunenfeld B, Pariente C. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clin Endocrinol (Oxf) 1990;33:271-278.
5. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 1990;336:1141-1144.
6. Tavaniotou A, Albano C, Van Steirteghem A, Devroey P. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix. Reprod Biomed Online 2003;6:421-426.
7. Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-1212.
8. Overes HW, de Leeuw R, Kloosterboer HJ. Regulation of aromatase activity in FSH-primed rat granulosa cells in vitro by follicle-stimulating hormone and various amounts of human chorionic gonadotrophin. Hum Reprod 1992;7:191-196.
9. Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990;70:421-430.
10. Licht P, Russu V, Lehmeyer S, Wildt L. Molecular aspects of direct LH/hCG effects on human endometrium - lessons from intrauterine microdialysis in the human female in vivo. Reprod Biol 2001;1:10-19.
11. Garcia-Velasco JA, Coelingh Bennink HJ, Epifanio R, Escudero E, Pellicer A, Simón C. High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist. Reprod Biomed Online 2007;15: 280-287.
12. Kilani Z, Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani L, Filicori M. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod 2003;18:1194-1199.
13. Tesarik J, Hazout A, Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 2003;7:59-64.
14. Prapas N, Prapas Y, Panagiotidis Y, Prapa S, Vanderzwalmen P, Schoysman R, Makedos G. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Hum Reprod 2005;20:1516-1520.
15. Prapas N, Prapas Y, Panagiotidis Y, Prapa S, Vanderzwalmen P, Makedos G. Cervical dilatation has a positive impact on the outcome of IVF in randomly assigned cases having two previous difficult embryo transfers. Hum Reprod 2004;19:1791-1795.
16. Prapas Y, Prapas N, Hatziparasidou A, Prapa S, Nijs M, Vanderzwalmen P, Vlassis G, Jones EE. The echoguide embryo transfer maximizes the IVF results. Acta Eur Fertil 1995;26:113-115.
17. Stokman PG, de Leeuw R, van den Wijngaard HA, Kloosterboer HJ, Vemer HM, Sanders AL. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril 1993;60:175-178.
18. Diczfalusy E, Harlin J. Clinical-pharmacological studies on humanmenopausal gonadotrophin. Hum Reprod 1988;3:21-27.
19. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988;297:1024-1026.
20. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188-191.
21. Ben-Amor AF. The effect of luteinizing hormone administered during the late follicular phase in normo-ovulatory women undergoing in-vitro fertilization. Hum Reprod 2000;15(Suppl 1):46.
22. Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002;5:104-108.
23. Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin α) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004;8:175-182.
24. Ferraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004;82:1521-1526.
25. Fanchin R, Peltier E, Frydman R, de Ziegler D. Human chorionic gonadotropin: does it affect human endometrial morphology in vivo? Semin Reprod Med 2001;19:31-35.
26. Li TC, Serle E, Warren MA, Cooke ID. Is endometrial development in the peri-implantation period influenced by high concentrations of luteinizing hormone in the follicular phase? Human Reprod 1993;8:1021-1024.
27. Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002;87:1156-1161.
28. Ottobre JS, Stouffer RL. Receptors for chorionic gonadotropin in the corpus luteum of the rhesus monkey during simulated early pregnancy: lack of down-regulation. Endocrinology 1986;119:1594-1602.
29. Mannaerts BM, Geurts TB, Odink J. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod 1998;13:1461-1464.
30. Noyes N, Liu HC, Sultan K, Schattman G, Rosenwaks Z. Endometrial thickness appears to be a significant factor in embryo implantation in in-vitro fertilization. Hum Reprod 1995;10:919-922.
31. Rinaldi L, Lisi F, Floccari A, Lisi R, Pepe G, Fishel S. Endometrial thickness as a predictor of pregnancy after in-vitro fertilization but not after intracytoplasmic sperm injection. Hum Reprod 1996;11:1538-1541.
32. De Geyter C, Schmitter M, De Geyter M, Nieschlag E, Holzgreve W, Schneider HP. Prospective evaluation of the ultrasound appearance of the endometrium in a cohort of 1,186 infertile women. Fertil Steril 2000;73:106-113.
33. Yuval Y, Lipitz S, Dor J, Achiron R. The relationships between endometrial thickness, and blood flow and pregnancy rates in in-vitro fertilization. Hum Reprod 1999;14:1067-1071.
34. Schild RL, Knobloch C, Dorn C, Fimmers R, van der Ven H, Hansmann M. Endometrial receptivity in an in vitro fertilization program as assessed by spiral artery blood flow, endometrial thickness, endometrial volume, and uterine artery blood flow. Fertil Steril 2001;75:361-366.
35. Lei ZM, Reshef E, Rao V. The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrial and myometrial blood vessels. J Clin Endocrinol Metab 1992;75:651-659.
36. Licht P, von Wolff M, Berkholz A, Wildt L. Evidence for cycle-dependent expression of full-length human chorionic gonadotropin/luteinizing hormone receptor mRNA in human endometrium and decidua. Fertil Steril 2003;79(Suppl 1):718-723.
37. Fazleabas AT, Donnelly KM, Srinivasan S, Fortman JD, Miller JB. Modulation of the baboon (Papio anubis) uterine endometrium by chorionic gonadotrophin during the period of uterine receptivity. Proc Natl Acad Sci U S A 1999;96:2543-2548.
38. Srisuparp S, Strakova Z, Brudney A, Mukherjee S, Reierstad S, Hunzicker-Dunn M, Fazleabas AT. Signal transduction pathways activated by chorionic gonadotropin in the primate endometrial epithelial cells. Biol Reprod 2003;68:457-464.
39. Licht P, Fluhr H, Neuwinger J, Wallwiener D, Wildt L. Is human chorionic gonadotropin directly involved in the regulation of human implantation? Mol Cell Endocrinol 2007;269:85-92.
40. Huber A, Hudelist G, Knöfler M, Saleh L, Huber JC, Singer CF. Effect of highly purified human chorionic gonadotropin preparations on the gene expression signature of stromal cells derived from endometriotic lesions: potential mechanisms for the therapeutic effect of human chorionic gonadotropin in vivo. Fertil Steril 2007;88(4 Suppl):1232-1239.
41. Herrler A, von Rango U, Beier HM. Embryo-maternal signalling: how the embryo starts talking to its mother to accomplish implantation. Reprod Biomed Online 2003;6:244-256.
42. Berndt S, Perrier d'Hauterive S, Blacher S, Péqueux C, Lorquet S, Munaut C, Applanat M, Hervé MA, Lamandé N, Corvol P, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J 2006;20:2630-2632.
43. Han SW, Lei ZM, Rao CV. Treatment of human endometrial stromal cells with chorionic gonadotropin promotes their morphological and functional differentiation into decidua. Mol Cell Endocrinol 1999;147:7-16.
44. Tang B, Gurpide E. Direct effect of gonadotropins on decidualization of human endometrial stroma cells. J Steroid Biochem Mol Biol 1993;47:115-121.
45. Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 2005;84:394-401.
46. Serafini P, Yadid I, Motta EL, Alegretti JR, Fioravanti J, Coslovsky M. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril 2006;86:830-838.
47. Berkkanoglu M, Isikoglu M, Aydin D, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril 2007;88:665-669.
48. Huirne JA, van Loenen AC, Schats R, McDonnell J, Hompes PG, Schoemaker J, Homburg R, Lambalk CB. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod 2005;20:359-367.